JP2019522030A - 肝性脳症の治療方法 - Google Patents

肝性脳症の治療方法 Download PDF

Info

Publication number
JP2019522030A
JP2019522030A JP2019504740A JP2019504740A JP2019522030A JP 2019522030 A JP2019522030 A JP 2019522030A JP 2019504740 A JP2019504740 A JP 2019504740A JP 2019504740 A JP2019504740 A JP 2019504740A JP 2019522030 A JP2019522030 A JP 2019522030A
Authority
JP
Japan
Prior art keywords
biotin
hepatic encephalopathy
treatment
patient
rats
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019504740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019522030A5 (OSRAM
Inventor
フレデリック、セデル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medday Pharmaceuticals
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of JP2019522030A publication Critical patent/JP2019522030A/ja
Publication of JP2019522030A5 publication Critical patent/JP2019522030A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019504740A 2016-07-29 2017-07-28 肝性脳症の治療方法 Ceased JP2019522030A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (en) 2016-07-29 2016-07-29 Method for treating hepatic encephalopathy
EP16305989.2 2016-07-29
PCT/EP2017/069194 WO2018020010A1 (en) 2016-07-29 2017-07-28 Method for treating hepatic encephalopathy

Publications (2)

Publication Number Publication Date
JP2019522030A true JP2019522030A (ja) 2019-08-08
JP2019522030A5 JP2019522030A5 (OSRAM) 2020-09-10

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019504740A Ceased JP2019522030A (ja) 2016-07-29 2017-07-28 肝性脳症の治療方法

Country Status (24)

Country Link
US (2) US10117854B2 (OSRAM)
EP (2) EP3275439A1 (OSRAM)
JP (1) JP2019522030A (OSRAM)
KR (1) KR20190034550A (OSRAM)
AU (1) AU2017303346A1 (OSRAM)
BR (1) BR112019001178A2 (OSRAM)
CA (1) CA3031302A1 (OSRAM)
CY (1) CY1122348T1 (OSRAM)
DK (1) DK3319601T3 (OSRAM)
EA (1) EA201990413A1 (OSRAM)
ES (1) ES2751154T3 (OSRAM)
HK (1) HK1254833B (OSRAM)
HR (1) HRP20191798T1 (OSRAM)
HU (1) HUE046590T2 (OSRAM)
IL (1) IL264460B (OSRAM)
LT (1) LT3319601T (OSRAM)
MA (1) MA42419B1 (OSRAM)
ME (1) ME03520B (OSRAM)
PL (1) PL3319601T3 (OSRAM)
PT (1) PT3319601T (OSRAM)
RS (1) RS59300B1 (OSRAM)
SI (1) SI3319601T1 (OSRAM)
SM (1) SMT201900628T1 (OSRAM)
WO (1) WO2018020010A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
MX387893B (es) * 2018-04-18 2025-03-19 Alparis Sa De Cv Nuevas fases solidas de rifaximina.
CN116173182A (zh) * 2023-03-31 2023-05-30 苏州融析生物科技有限公司 醋酸格拉替雷药物组合物在肝硬化预防及治疗药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01226814A (ja) * 1988-03-05 1989-09-11 Sansei Seiyaku Kk 高アンモニア血症治療剤
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20130084334A1 (en) * 2010-04-06 2013-04-04 Assistance Publique - Hopitaux De Paris Pharmaceutical compositions highly dosed with biotin
JP2015522630A (ja) * 2012-07-26 2015-08-06 アシスタンス ピュブリック−オピト ド パリＡｓｓｉｓｔａｎｃｅ Ｐｕｂｌｉｑｕｅ−Ｈｏｐｉｔａｕｘ Ｄｅ Ｐａｒｉｓ 多発性硬化症治療のためのビオチンの使用
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
WO2014177286A1 (en) 2013-04-29 2014-11-06 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01226814A (ja) * 1988-03-05 1989-09-11 Sansei Seiyaku Kk 高アンモニア血症治療剤
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
US20130084334A1 (en) * 2010-04-06 2013-04-04 Assistance Publique - Hopitaux De Paris Pharmaceutical compositions highly dosed with biotin
JP2015522630A (ja) * 2012-07-26 2015-08-06 アシスタンス ピュブリック−オピト ド パリＡｓｓｉｓｔａｎｃｅ Ｐｕｂｌｉｑｕｅ−Ｈｏｐｉｔａｕｘ Ｄｅ Ｐａｒｉｓ 多発性硬化症治療のためのビオチンの使用
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品

Also Published As

Publication number Publication date
EA201990413A1 (ru) 2019-06-28
MA42419A (fr) 2018-05-16
US20180214417A1 (en) 2018-08-02
PL3319601T3 (pl) 2020-06-29
MA42419B1 (fr) 2019-11-29
IL264460B (en) 2021-06-30
DK3319601T3 (da) 2019-11-18
EP3275439A1 (en) 2018-01-31
BR112019001178A2 (pt) 2019-04-30
US20190070150A1 (en) 2019-03-07
CA3031302A1 (en) 2018-02-01
WO2018020010A1 (en) 2018-02-01
HK1254833B (en) 2020-05-22
CY1122348T1 (el) 2021-01-27
RS59300B1 (sr) 2019-10-31
ES2751154T3 (es) 2020-03-30
EP3319601A1 (en) 2018-05-16
LT3319601T (lt) 2019-11-11
SMT201900628T1 (it) 2020-01-14
US10117854B2 (en) 2018-11-06
KR20190034550A (ko) 2019-04-02
PT3319601T (pt) 2019-09-18
HRP20191798T1 (hr) 2019-12-27
HUE046590T2 (hu) 2020-03-30
EP3319601B1 (en) 2019-08-28
US10328059B2 (en) 2019-06-25
AU2017303346A1 (en) 2019-01-31
ME03520B (me) 2020-04-20
IL264460A (en) 2019-02-28
SI3319601T1 (sl) 2019-11-29

Similar Documents

Publication Publication Date Title
RU2519660C2 (ru) Режим дозировки селективного агониста рецептора s1p1
US7834056B2 (en) Pharmaceutical composition for gout
JP2020186241A (ja) 酸素化コレステロール硫酸塩（ｏｃｓ）の使用
US20170151200A1 (en) Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
JP3906716B2 (ja) 耐糖能異常用薬剤
JP2010531872A (ja) アルコール摂取症状を軽減するための方法
JP2019522030A (ja) 肝性脳症の治療方法
CN108366983A (zh) L-鸟氨酸苯乙酸盐制剂
HK1254833A1 (en) Method for treating hepatic encephalopathy
JP6044667B2 (ja) 耐糖能異常用医薬組成物及び飲食品
EP1997485A1 (en) Pharmaceutical composition comprising meglitinide for prevention of hepatic fibrosis
WO2017084631A9 (zh) 预防或治疗脂肪胰、改善脂肪胰引起的胰病变、糖尿病或其他相关病症之组合物及方法
JP4715423B2 (ja) 耐糖能異常用医薬組成物及び飲食品
JP2020536092A (ja) 細菌感染症の治療方法
Watson Effects of concurrent drug therapy and of feeding on plasma chloramphenicol levels after oral administration of chloramphenicol in dogs
EP4554589A1 (en) Solid oral dosage form comprising vortioxetine and vitamin d
WO2024217522A1 (zh) 一种异噻唑并[5,4-d]嘧啶类化合物治疗炎性疾病的用途
EP1462149B1 (de) Verwendung von Phenazon zur Behandlung von Migräne
JP2024505246A (ja) 神経変性認知障害を治療するための、コリンエステラーゼ阻害薬と四級アンモニウム抗ムスカリン剤との固定用量配合剤
CN117653642A (zh) 格列本脲促进nad+水平的用途
CN118871096A (zh) 包含l-色氨酸、l-5-羟基色氨酸和外周降解抑制剂的药物组合物和药物
Conti et al. Fluoxetine in the management of chronic itch in a cat: a case report
WO2012110946A1 (en) Pharmaceutical composition comprising the pde4 enzyme inhibitor revamilast and a disease modifying agent, preferably methotrexate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200728

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200728

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210716

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20211126